শুধুমাত্র তথ্যমূলক — চিকিৎসা পরামর্শ নয়। সর্বদা লাইসেন্সপ্রাপ্ত স্বাস্থ্যসেবা প্রদানকারীর পরামর্শ নিন।

MedBD
EN
Community data Updated 2 মাস আগে
🌐 View in English

ইঙ্গিত

Cancer

Buviren is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. Its efficacy has been established in patients with HCV genotype 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria who are awaiting liver transplantation, as well as those with HCV/HIV-1 co-infection. A few points should be kept in mind when starting treatment with Buviren. It should not be used as monotherapy for CHC, since it is only meant to be given as part of a combination regimen. The specific treatment regimen and its duration depend on both the viral genotype and the patient population being treated. Treatment response can also vary depending on baseline host and viral factors.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

ফার্মাকোলজি

Sofosbuvir is a nucleotide analog inhibitor that specifically blocks the HCV NS5B RNA-dependent RNA polymerase, an enzyme the hepatitis C virus needs to copy its genetic material. Once inside cells, sofosbuvir is metabolized into its active form, a uridine analog triphosphate (GS-461203). This active form is then incorporated into the growing HCV RNA chain by the NS5B polymerase, where it acts as a chain terminator, stopping further RNA synthesis. More specifically, sofosbuvir binds to the two Mg2+ ions located in the GDD active site motif of the NS5B polymerase, and by doing so, it blocks the enzyme's activity and prevents the virus from replicating further.

Pregnancy & Breastfeeding

During pregnancy (Category B), there are no adequate and well-controlled studies of sofosbuvir in pregnant women. For nursing mothers, it is not known whether sofosbuvir and its metabolites pass into human breast milk.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: One 400 mg tablet taken once daily with or without food. Should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC.Recommended combination therapy: (HCV Mono-infected and HCV/HIV-1 Co-infected)- Genotype 1 or 4: Sofosbuvir + Peginterferon alfa + Ribavirin for 12 weeks Genotype 2: Sofosbuvir + Ribavirin for 12 weeks Genotype 3: Sofosbuvir + Ribavirin for 24 weeks Sofosbuvir in combination with Ribavirin for 24 weeks can be considered for CHC patients with genotype 1 infection who are Interferon ineligibleShould be used in combination with Ribavirin for treatment of CHC in patients with hepatocellular carcinoma awaiting liver transplantation for up to 48 weeks or until liver transplantation whichever occurs firstA dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease

পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া

পার্শ্বপ্রতিক্রিয়া

No side-effect data recorded yet.